Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study)
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Acute chest syndrome (ACS) is a frequent and potentially life-threatening pulmonary illness.
It is a complication of sickle cell disease and is the leading cause of death from this
disease in adults. Several pathologic processes are recognized causes of ACS, including
infectious diseases, hypoventilation secondary to chest pain, in situ thrombosis and
pulmonary fat embolism. Inhaled nitric oxide (iNO) has been shown to be a pulmonary
vasodilatator with minimal systemic effects and has also been shown to improve gas exchange
in both animal and human acute lung injury (ALI).
The combined effects of iNO gas of improving pulmonary ventilation to perfusion matching,
reducing alveolar and systemic inflammation, modulate the course of acute chest syndrome,
which combine the physiopathology of vaso-occlusive crisis and acute lung injury.
We hypothesise inhaled NO will improve oxygenation and clinical outcome of sickle cell
disease patients with acute chest syndrome.